TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies, announced its participation in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 3:30 p.m. Eastern Time. The presentation will be accessible via webcast on the Company’s website. TScan is developing lead therapy candidates TSC-100 and TSC-101 for treating hematologic malignancies, aiming to eliminate residual disease post-transplantation. Additionally, the company is building its ImmunoBank to provide customized therapies targeting various solid tumors.

Positive

• Participation in the H.C. Wainwright Cell Therapy Virtual Conference increases visibility of TScan's TCR-T therapies.
• Active development of TSC-100 and TSC-101 for hematologic malignancies addresses significant market needs.
• Building the ImmunoBank enhances TScan's capability to offer customized treatment options for solid tumors.

Negative

• None.

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023, at 3:30 p.m. Eastern Time.

A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com

FAQ

When is TScan Therapeutics presenting at the H.C. Wainwright Cell Therapy Conference?

TScan Therapeutics will present on February 28, 2023, at 3:30 p.m. Eastern Time.

What are TScan Therapeutics' lead therapy candidates?

TScan's lead therapy candidates are TSC-100 and TSC-101, aimed at treating hematologic malignancies.

How can I access the webcast of TScan's presentation?

The webcast of TScan's presentation will be available on the Company's website in the 'Events and Presentations' section.

What is the focus of TScan Therapeutics?

TScan Therapeutics focuses on developing T cell receptor-engineered T cell therapies for cancer treatment.